Temporary Treatment during Primary HIV Infection Does Not Affect Virologic Response to Subsequent Long-Term Treatment

Aim. To summarize the experience of a multidisciplinary therapy hospital in treating patients with hepatitis C virus (HCV)-associated cryoglobulinemic vasculitis (CV). Subjects and methods. Seventy-two patients (mean age, 49.4±10.3 years) with HCV-associated CV were examined and followed up for an average period of 2.8±3.6 years. The efficiency of traditional (corticosteroids ± cyclophosphamide) and selective (rituximab) immunosuppressive therapy (IST) was estimated in 31 and 15 observations, respectively, and that of antiviral therapy (AVT) in 25. Vasculitis activity was assessed using the Birmingham vasculitis activity score (BVAS). The patients’ survival was studied; multivariate logistic regression analysis was carried out. Results. 24 (33.4%) of the 72 patients had a stage of liver cirrhosis (LC). The pretreatment mean BVAS was 11.9±7.2 (range 2 to 36). Severe CV (BVAS ≥15) was present in 30.6% of the patients. AVT was accompanied by achievement of sustained virologic response in 48% of the patients, clinical remission in 68% and had an advantage over IST in relation to long-term treatment results. Rituximab was significantly more effective than traditional immunosuppressants (remission rates of 73 and 13%, respectively). Combined therapy (rituximab and AVT) was most effective in patients with severe forms of vasculitis. Sixteen patients died from complications of vasculitis (37.5%), infection (37.5%), and LC (25%). The factors adversely affecting prognosis were age >55 years (odds ratio (OR), 4.49), the presence of LC (OR, 3.68), renal failure (OR, 4.66) and the use of glucocorticosteroids (OR, 3.91). Conclusion. HCV-associated CV can determine the prognosis of chronic HСV infection. AVT is the treatment of choice in all patients with HСV-associated CV. AVT must be combined with rituximab therapy in patients with severe forms of vasculitis.

Download Full-text

Long-term treatment for lipoatrophy associated or not with HIV infection using ePTFE implants and polyacrylamide gel

Aesthetic Surgery Journal ◽

10.1016/j.asj.2005.09.006 ◽

2005 ◽

Vol 25 (6) ◽

pp. 561-570 ◽

Cited By ~ 5

Author(s):

B MOLE

Keyword(s):

Hiv Infection ◽

Term Treatment ◽

Polyacrylamide Gel ◽

Long Term Treatment

Download Full-text

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

BMC Infectious Diseases ◽

10.1186/s12879-015-0892-1 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 1

Author(s):

Evguenia Krastinova ◽

◽

Remonie Seng ◽

Jerome Lechenadec ◽

Henri Panjo ◽

...

Keyword(s):

Hiv Infection ◽

Virologic Response ◽

Primary Hiv Infection

Download Full-text

Long-Term Treatment of HIV-Infected MT-4 Cells in Culture with HIV Proteinase Inhibitor RO 31-8959 Leads to Complete Cure of Infection

Antiviral Chemistry and Chemotherapy ◽

10.1177/095632029400500405 ◽

1994 ◽

Vol 5 (4) ◽

pp. 236-242 ◽

Cited By ~ 4

Author(s):

H. Nitschko ◽

H. Lindhofer ◽

H. Schätzl ◽

J. Eberle ◽

G. Deby ◽

...

Keyword(s):

Cell Culture ◽

Cell Death ◽

Hiv Infection ◽

Proteinase Inhibitor ◽

Proteinase Inhibitors ◽

Antiviral Effect ◽

Term Treatment ◽

Long Term Treatment ◽

Drug Removal

An HIV-infected cell culture was treated with the specific HIV proteinase inhibitor Ro 31-8959 for three months to analyse the antiviral effect and possible cytotoxicity of the drug in long-term treatment. The drug was added 1 h after HIV infection with 0.002 m.o.i. and maintained for 87 days in the cell culture. There was no detectable cell death nor any evidence of HIV production in this time. Cells were proven to be initially infected, since premature drug removal led to a re-emergence of infectious HIV and cell death. However, after 87 days of treatment the drug could be removed safely and HIV was cleared demonstrably from the culture. These data suggest that long-term dosage may be advantageous to the clinical treatment of HIV infection by HIV proteinase inhibitors.

Download Full-text

Bilateral Thyroarytenoid Denervation: A New Treatment for Laryngeal Hyperadduction Disorders Studied in the Canine

Otolaryngology ◽

10.1177/019459989210700508 ◽

1992 ◽

Vol 107 (5) ◽

pp. 657-668 ◽

Cited By ~ 11

Author(s):

Joel A. Sercarz ◽

Gerald S. Berke ◽

Ye Ming ◽

James Rothschiller ◽

Michael C. Graves

Keyword(s):

Thyroid Cartilage ◽

Term Treatment ◽

Spasmodic Dysphonia ◽

Laryngeal Function ◽

Adductor Spasmodic Dysphonia ◽

Long Term Treatment ◽

Temporary Treatment ◽

New Treatment ◽

Uncertain Etiology

Adductor spasmodic dysphonia is a vocal disorder of uncertain etiology with no satisfactory long-term treatment. Recently, injection of botulinum toxin (Botox) into the thyroarytenoid (TA) muscle has been used as an effective temporary treatment. A surgical counterpart to bilateral TA Botox injection is described in this article. Bilateral thyroarytenoid denervation was performed through a window in the thyroid cartilage in seven canines, including four that were studied 3 months after the procedure. No serious complications occurred in the animals, each maintaining full vocal fold abduction and adduction. In all cases, anticipated physiologic changes in laryngeal function were observed, including the inability to generate high subglottic pressures during high levels of laryngeal nerve (RLN) stimulation. In two of the surviving animals, the ansa cervicalis was used to reinnervate the TA muscle, thereby preventing the possibility of reinnervation from the proximal RLN stump while limiting TA atrophy and fibrosis. Bilateral TA denervation represents a hopeful new long-term approach to spasmodic dysphonia treatment.

Download Full-text